Valeant Pharmaceuticals surprised the industry late last week when it upped its offer to acquire Allergan, the second such bid increase in a single week.
The Canadian company reportedly boosted its offer to $53 billion to acquire the Botox manufacturer. The offer stacks up at $72 a share, increased from last …read more
Source: Global Competition Law Blogs